Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMBNASDAQ:CRBPNASDAQ:NBSENASDAQ:OBSVNASDAQ:ONCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$18.56+2.3%$15.14$7.75▼$19.93$138.55M0.6227,492 shs27,519 shsCRBPCorbus Pharmaceuticals$7.30-5.3%$7.74$4.64▼$61.90$94.35M3.05341,061 shs86,437 shsNBSENeuBase Therapeutics$0.38$0.38$0.36▼$4.80$1.43MN/AN/AN/AOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs300 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences+2.26%+2.43%+14.29%+124.70%+40.50%CRBPCorbus Pharmaceuticals-4.05%+5.80%-20.91%+35.44%-85.49%NBSENeuBase Therapeutics0.00%0.00%0.00%0.00%0.00%OBSVObsEva0.00%0.00%0.00%0.00%0.00%ONCSOncoSec Medical0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASMBAssembly Biosciences3.7423 of 5 stars3.33.00.04.72.30.00.0CRBPCorbus Pharmaceuticals3.7975 of 5 stars3.60.00.04.71.32.50.6NBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.67Moderate Buy$33.0077.80% UpsideCRBPCorbus Pharmaceuticals 3.10Buy$50.88596.92% UpsideNBSENeuBase Therapeutics 0.00N/AN/AN/AOBSVObsEva 0.00N/AN/AN/AONCSOncoSec Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OBSV, ONCS, CRBP, NBSE, and ASMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.005/7/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.005/7/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$32.15M4.41N/AN/A$5.25 per share3.54CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$40.18M-$6.23N/AN/AN/A-124.15%-131.77%-36.81%8/6/2025 (Estimated)CRBPCorbus Pharmaceuticals-$40.21M-$4.22N/AN/AN/AN/A-36.87%-32.87%8/5/2025 (Estimated)NBSENeuBase Therapeutics-$4.37MN/A0.00∞N/AN/AN/AN/AN/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/AONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/ALatest OBSV, ONCS, CRBP, NBSE, and ASMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025CRBPCorbus Pharmaceuticals-$1.35N/AN/AN/AN/AN/A5/8/2025Q1 2025ASMBAssembly Biosciences-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 million5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A2.052.05CRBPCorbus PharmaceuticalsN/A11.8211.82NBSENeuBase TherapeuticsN/AN/AN/AOBSVObsEvaN/A0.610.61ONCSOncoSec MedicalN/A0.890.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%CRBPCorbus Pharmaceuticals64.64%NBSENeuBase Therapeutics12.37%OBSVObsEva17.52%ONCSOncoSec Medical8.69%Insider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.30%CRBPCorbus Pharmaceuticals4.00%NBSENeuBase Therapeutics7.90%OBSVObsEva14.40%ONCSOncoSec Medical1.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences1007.64 million7.25 millionOptionableCRBPCorbus Pharmaceuticals4012.24 million11.75 millionOptionableNBSENeuBase Therapeutics403.75 million3.46 millionNot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionableOBSV, ONCS, CRBP, NBSE, and ASMB HeadlinesRecent News About These CompaniesPVCT Provectus Biopharmaceuticals, Inc.August 25, 2024 | seekingalpha.comIs OncoSec Medical Inc (ONCSQ) Stock a Good Investment?June 29, 2023 | aaii.comAONCS - OncoSec Medical IncorporatedJune 24, 2023 | finance.yahoo.com0 analysts rank ONCS stock as an OverweightJune 23, 2023 | knoxdaily.comKWhy Is OncoSec Medical (ONCS) Stock Up 100% Today?June 23, 2023 | markets.businessinsider.comWhy John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionJune 15, 2023 | msn.comWhy Is OncoSec Medical (ONCS) Stock Down 48% Today?June 15, 2023 | msn.comOncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 18, 2023 | finance.yahoo.comOncoSec Medical plunges 35% lower on sale of 1.4M shares of common stockMay 16, 2023 | msn.comOncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 16, 2023 | finance.yahoo.comOncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical programMay 16, 2023 | finance.yahoo.comOncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL ProgramApril 27, 2023 | finance.yahoo.comOncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesApril 11, 2023 | finance.yahoo.comWhy OncoSec Medical Shares Are Soaring TodayApril 10, 2023 | msn.comOncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesApril 10, 2023 | finance.yahoo.comOncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket TradingApril 6, 2023 | benzinga.comOncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting StudyApril 3, 2023 | finance.yahoo.comOncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trialApril 3, 2023 | msn.comOncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 TreatmentApril 3, 2023 | finance.yahoo.comOncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%March 1, 2023 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOBSV, ONCS, CRBP, NBSE, and ASMB Company DescriptionsAssembly Biosciences NASDAQ:ASMB$18.56 +0.42 (+2.32%) As of 07/7/2025 04:00 PM EasternAssembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Corbus Pharmaceuticals NASDAQ:CRBP$7.30 -0.41 (-5.32%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$7.32 +0.02 (+0.22%) As of 07:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.NeuBase Therapeutics NASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.OncoSec Medical NASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
